IONSIonis Pharmaceuticals, Inc.
Price
-26%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, growth fading, the market undecided.
TRYNGOLZA is approved in the United States, or U.S., as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome, or FCS, and is approved in the European Union, or EU, for patients with genetically confirmed FCS. TRYNGOLZA is also approved in Canada. TRYNGOLZA is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides clinically meaningful reduction in acute pancreatitis, or AP, events when used with an appropriate diet (≤20 grams of fat per day).
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Ionis Pharmaceuticals, Inc. (IONS) reported revenue of $268M in Q2 2026 (quarter ended Jun 30, 2026), down 41% from the same quarter a year earlier. That came with a gross margin of 99% and net loss of $115M. For the full year FY2025, revenue was $944M (+34% year on year) and net income −$381M. Its largest product in Q2 2026 was Royalty at $76M, 28% of the disclosed total, ahead of Spinraza Royalties at 19%. The next results filing is expected around Oct 28, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 23, 2026On September 23, 2026, Ionis and its partner, Roche, announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with IgAN. The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningful …Regulation FD disclosure · Form 8-K
- Sep 4, 2026On September 4, 2026, Ionis announced that its partner, Novartis, reported that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction …Regulation FD disclosure · Form 8-K
- Sep 4, 2026On September 3, 2026, Ionis announced that the U.S. FDA has approved ZANVASTRO™ (zilganersen) for the treatment of AxD in pediatric and adult patients.Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $275.8MThe company’s own SEC segment disclosure.
- Royalty$76.0M28%
- Spinraza Royalties$53.5M19%
- Salanersen$45.0M16%
- DAWNZERA Sales$26.6M10%
- Sapablursen$20.0M7%
- Wainus Royalties$16.4M6%
- Other (4)$38.3M14%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.